Literature DB >> 8427040

Beta-propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus.

S Morgeaux1, N Tordo, C Gontier, P Perrin.   

Abstract

The effects of beta-propiolactone (BPL), an alkylating and virus inactivating agent, on the structural and in vitro biological properties of different DNA preparations from BHK-21 cells were investigated. Both uninfected and rabies virus-infected cells were used. Purified cellular DNA (celDNA) was used as the reference, and supernatants from infected cells were treated with BPL. For structural and biological studies three types of DNA preparation were tested: celDNA; purified DNA from cell (infected or uninfected) supernatant (pcsDNA) with or without BPL treatment; and residual cell DNA present in purified rabies virus (inactivated or not) preparations. Rabies infection and BPL (diluted 1:4000) treatment induced modifications in the structure of the three DNA types, including strand breaks and nicks. The damage to the DNA structure by BPL modifies the biological properties of the pcsDNA appraised by its ability to serve as the template in vitro for different polymerases. When rabies virus was inactivated with BPL diluted 1:1000 the DNA damage increased dramatically: small double-stranded DNA fragments (50-200 base pairs) were generated which could not function as templates for polymerases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427040     DOI: 10.1016/0264-410x(93)90343-v

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Evaluation of the serum-free medium MDSS2 for the production of poliovirus on vero cells in bioreactors.

Authors:  O W Merten; R Wu; E Couvé; R Crainic
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

2.  A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects.

Authors:  H X Lin; C Gontier; M F Saron; P Perrin
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX.

Authors:  Khaled Trabelsi; Meriem Ben Zakour; Ingo Jordan; Volker Sandig; Samia Rourou; Hela Kallel
Journal:  BMC Biotechnol       Date:  2022-06-17       Impact factor: 3.329

4.  Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine.

Authors:  David Onions; William Egan; Ruth Jarrett; Deborah Novicki; Jens-Peter Gregersen
Journal:  Biologicals       Date:  2010-09       Impact factor: 1.856

5.  Monophosphoryl-Lipid A (MPLA) is an Efficacious Adjuvant for Inactivated Rabies Vaccines.

Authors:  Chen Chen; Chengguang Zhang; Ruiming Li; Zongmei Wang; Yueming Yuan; Haoqi Li; Zhenfang Fu; Ming Zhou; Ling Zhao
Journal:  Viruses       Date:  2019-12-03       Impact factor: 5.048

6.  Staphylococcus aureus derived hyaluronic acid and bacillus Calmette-Guérin purified proteins as immune enhancers to rabies vaccine and related immuno-histopathological alterations.

Authors:  Rania Ibrahim Shebl; Mohamed E Amer; Tamer M M Abuamara; Emadeldin R Matar; Hassan Fathy Ahmed; Tamer Albasyoni Gomah; Laila E El Moselhy; Mohammed Abu-Elghait; Aly Fahmy Mohamed
Journal:  Clin Exp Vaccine Res       Date:  2021-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.